Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.60 |
| ▸ | BRS3 | P32247 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.60 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.60 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.60 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL29772327 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL19535 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL30426884 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29360040 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL29691369 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2516731 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL6758624 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL6320176 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 48966 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075405-A | Compound omeprazole dry suspension and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-116794308-B | Application of beta-1, 4-galactosyltransferase 1 and inhibitor thereof in preparation of medicines for treating acute and chronic liver diseases | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026101534-A1 | MYOSTATIN AND ACTIVIN A IMMUNOGENS AND METHODS OF USE | VAXXINITY, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026097604-A1 | COMPOSITION AND DRUG-DEVICE COMBINATION PRODUCT FOR LOCAL TUMOR ADMINISTRATION, AND USE | 诺曼德美国有限责任公司 | 2026-05-15 | — | — | WO | claimed |
| US-12622900-B2 | Methods and compositions for treating gastric ulcers | Luoda Pharma Limited (IE) | 2026-05-12 | — | — | US | claimed |
| EP-4735895-A1 | HELICOBACTER CAGA PEPTIDES AND THEIR USE IN DIAGNOSIS | Biotome Pty Ltd (AU) | 2026-05-06 | — | — | EP | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| WO-1989003829-A1 | OMEPRAZOLE FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | claimed |
| WO-1989003830-A1 | 2-PYRIDINYLMETHYL (SULFINYL OR THIO)BENZIMIDAZOLES FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | claimed |
| EP-0103553-B1 | INTERMEDIATES FOR THE PREPARATION OF OMEPRAZOLE | Aktiebolaget Hässle (SE) | 1989-02-22 | — | — | EP | claimed |
| US-4786505-A | OMEPRAZOLE, ANTISECRETORY AGENTS | AKTIEBOLAGET HASSLE (SE) | 1988-11-22 | — | — | US | claimed |
| EP-0247983-A2 | New pharmaceutical preparation for oral use | Aktiebolaget Hässle (SE) | 1987-12-02 | — | — | EP | claimed |
| EP-0244380-A2 | Pharmaceutical formulations of acid labile substances for oral use | Aktiebolaget Hässle (SE) | 1987-11-04 | — | — | EP | claimed |
| EP-0124495-B1 | OMEPRAZOLE SALTS | Aktiebolaget Hässle (SE) | 1987-01-14 | — | — | EP | claimed |
| US-4620008-A | Processes for the preparation of omeprazole and intermediates therefore | AKTIEBOLAGET HASSLE (SE) | 1986-10-28 | — | — | US | claimed |
| EP-0124495-A2 | Omeprazole salts | Aktiebolaget Hässle (SE) | 1984-11-07 | — | — | EP | claimed |
| EP-0103553-A1 | Intermediates for the preparation of omeprazole | Aktiebolaget Hässle (SE) | 1984-03-21 | — | — | EP | claimed |